Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | PLAT | P00750 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.40 |
| ▸ | TACR3 | P29371 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.35 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.35 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CPN1 | P15169 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL790440 | 1.00 | PLG (0.42) | PLGPLATLMNACHRM2CHRM1 | |
| SCHEMBL3155411 | 1.00 | PLG (0.42) | PLGPLATLMNACHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL25287438 | 0.98 | PLG (0.41) | PLGPLATLMNACHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL25248778 | 0.98 | PLG (0.41) | PLGPLATLMNACHRM2CHRM1 | |
| Tert-Butanol SCHEMBL28550813 | 0.91 | CHRM2 (0.43) | PLGPLATLMNACHRM2CHRM1 | |
| SCHEMBL1694214 | 0.88 | ITGB3 (0.43) | PLGPLATLMNACHRM2CHRM1 | |
| SCHEMBL1694358 | 0.88 | ITGB3 (0.43) | PLGPLATLMNACHRM2CHRM1 | |
| SCHEMBL856443 | 0.88 | ITGB3 (0.43) | PLGPLATLMNACHRM2CHRM1 | |
| SCHEMBL600521 | 0.87 | PLG (0.50) | PLGPLATLMNACHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL5249863 | 0.85 | PLG (0.48) | PLGPLATLMNACHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104080335-A | Certain chemical entities, compositions, and methods | QIAN XIANGPING | 2014-10-01 | — | — | CN | claimed |
| EP-4463452-A2 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | Anima Biotech Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| WO-2024105007-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-11958833-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-04-16 | — | — | US | disclosed |
| EP-3730484-B1 | INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | HINOVA PHARMACEUTICALS INC (CN) | 2024-02-28 | — | — | EP | disclosed |
| CN-117586180-A | Compounds useful as inhibitors of voltage-gated sodium channels | 广州费米子科技有限责任公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-117412964-A | Substituted heterocyclic compounds and their use | 首药控股(北京)股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| WO-2023244917-A1 | 1,8-NAPHTHYRIDIN-2-ONE HETEROBIFUNCTIONAL BCL6 DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| EP-4274569-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | Anima Biotech Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| WO-2023177700-A2 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2011056635-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| CN-102007128-A | Tricyclic antibiotics | ACTELION PHARMACEUTICALS LTD | 2011-04-06 | — | — | CN | disclosed |
| CN-101678015-A | Pyrrolo (3, 2, 1-ij) quinoline-4-one derivatives for treating tuberculosis | GLAXO GROUP LTD | 2010-03-24 | — | — | CN | disclosed |
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2009062059-A2 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| CN-101346379-A | Per-cyclic tricyclic compounds useful as antibacterial agents | GLAXO GROUP LTD (GB) | 2009-01-14 | — | — | CN | disclosed |
| US-20070259855-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
| EP-1784393-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006028904-A9 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006028904-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PRKCE, PRKCZ, PRKCQ | PLG 2714/4885PLAT 1951/4885LMNA 1375/4885 |
| US-20070259855-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | ROR1, RORB, RORA | PLG 3508/4885PLAT 3862/4885LMNA 3473/4885 |
| US-11958833-B2 | Compounds | USP30, USP20, USP10 | PLG 3553/4885PLAT 4602/4885LMNA 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.